{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:23:17Z","timestamp":1785378197764,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00520-020-05906-y","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T20:55:04Z","timestamp":1606164904000},"page":"1129-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-1956","authenticated-orcid":false,"given":"Tim","family":"Cooksley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"5906_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.2020.3072","volume":"323","author":"C Del Rio","year":"2020","unstructured":"Del Rio C, Malani PN (2020) COVID-19-new insights on a rapidly changing epidemic. JAMA 323:1339\u20131340","journal-title":"JAMA"},{"key":"5906_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497\u2013506","journal-title":"Lancet"},{"issue":"3","key":"5906_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335\u2013337","journal-title":"Lancet Oncol"},{"key":"5906_CR4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","volume":"31","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 31:894\u2013901","journal-title":"Ann Oncol"},{"key":"5906_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejca.2020.04.017","volume":"132","author":"D Trapani","year":"2020","unstructured":"Trapani D, Marra A, Curigliano G (2020) The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy region. Eur J Cancer 132:199\u2013206","journal-title":"Eur J Cancer"},{"key":"5906_CR6","doi-asserted-by":"crossref","unstructured":"Lee L, Cazier J, Starkey T et al;\u00a0UK Coronavirus Cancer Monitoring Project Team (2020)\u00a0COVID-19 prevalence and mortality in patients with\u00a0cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 21(10):1309-1316","DOI":"10.1016\/S1470-2045(20)30442-3"},{"key":"5906_CR7","first-page":"JCO2001307","volume":"2020","author":"J Jee","year":"2020","unstructured":"Jee J, Foote MB, Lumish M et al (2020) Chemotherapy and COVID-19 outcomes in patients with cancer [published online ahead of print]. J Clin Oncol 2020:JCO2001307","journal-title":"J Clin Oncol"},{"issue":"6","key":"5906_CR8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z et al (2020) Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 10(6):783\u2013791","journal-title":"Cancer Discov"},{"key":"5906_CR9","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1111\/bjh.16852","volume":"190","author":"J Aries","year":"2020","unstructured":"Aries J, Davies J, Auer R et al (2020 (Epub ahead of print)) Clinical outcome of coronavirus disease 19 in haemato-oncology patients. Br J Haematol 190:e64\u2013e67","journal-title":"Br J Haematol"},{"key":"5906_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"M Garassino","year":"2020","unstructured":"Garassino M, Whisenant J, Huang L, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, de Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, la Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L, TERAVOLT investigators (2020 (epub ahead of print)) COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 21:914\u2013922","journal-title":"Lancet Oncol"},{"key":"5906_CR11","doi-asserted-by":"publisher","first-page":"e00512","DOI":"10.1128\/JCM.00512-20","volume":"58","author":"Y Tang","year":"2020","unstructured":"Tang Y, Schmitz JE, Persing DH et al (2020) Laboratory diagnosis of COVID-19: current issues and challenges. J Clin Microbiol 58:e00512\u2013e00520","journal-title":"J Clin Microbiol"},{"issue":"20","key":"5906_CR12","doi-asserted-by":"publisher","first-page":"30314","DOI":"10.1016\/j.clon.2020.07.020","volume":"S0936\u20136555","author":"R Berman","year":"2020","unstructured":"Berman R, Davies A, Cooksley T et al (2020) Supportive care: an indispensable component of modern oncology [published online ahead of print, 2020 Aug 16]. Clin Oncol (R Coll Radiol) S0936\u20136555(20):30314\u201330319. https:\/\/doi.org\/10.1016\/j.clon.2020.07.020","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"5906_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.seminoncol.2020.02.005","volume":"47","author":"K Bochennek","year":"2020","unstructured":"Bochennek K, Luckowitsch M, Lehrnbecher T (2020) Recent advances and future directions in the management of the immunocompromised host. Semin Oncol 47(1):40\u201347. https:\/\/doi.org\/10.1053\/j.seminoncol.2020.02.005","journal-title":"Semin Oncol"},{"issue":"2","key":"5906_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.idc.2019.01.001","volume":"33","author":"S Atkins","year":"2019","unstructured":"Atkins S, He F (2019) Chemotherapy and beyond: infections in the era of old and new treatments for hematologic malignancies. Infect Dis Clin N Am 33(2):289\u2013309. https:\/\/doi.org\/10.1016\/j.idc.2019.01.001","journal-title":"Infect Dis Clin N Am"},{"issue":"3","key":"5906_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.seminoncol.2011.03.013","volume":"38","author":"BL Rapoport","year":"2011","unstructured":"Rapoport BL (2011) Management of the cancer patient with infection and neutropenia. Semin Oncol 38(3):424\u2013430. https:\/\/doi.org\/10.1053\/j.seminoncol.2011.03.013","journal-title":"Semin Oncol"},{"issue":"5","key":"5906_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5603\/ARM.2018.0039","volume":"86","author":"S Chrysikos","year":"2018","unstructured":"Chrysikos S, Karampitsakos T, Tzouvelekis A, Dimakou K (2018) Endobronchial metastasis from renal cell carcinoma as a reason for recurrent pulmonary infections. Adv Respir Med 86(5):245\u2013248. https:\/\/doi.org\/10.5603\/ARM.2018.0039","journal-title":"Adv Respir Med"},{"issue":"29","key":"5906_CR17","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.3748\/wjg.v23.i29.5386","volume":"23","author":"GQ Zhang","year":"2017","unstructured":"Zhang GQ, Li Y, Ren YP, Fu NT, Chen HB, Yang JW, Xiao WD (2017) Outcomes of preoperative endoscopic nasobiliary drainage and endoscopic retrograde biliary drainage for malignant distal biliary obstruction prior to pancreaticoduodenectomy. World J Gastroenterol 23(29):5386\u20135394. https:\/\/doi.org\/10.3748\/wjg.v23.i29.5386","journal-title":"World J Gastroenterol"},{"issue":"6","key":"5906_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/sur.2016.033","volume":"17","author":"LC Smit","year":"2016","unstructured":"Smit LC, Bruins MJ, Patijn GA, Ruijs GJ (2016) Infectious complications after major abdominal cancer surgery: in search of improvable risk factors. Surg Infect 17(6):683\u2013693. https:\/\/doi.org\/10.1089\/sur.2016.033","journal-title":"Surg Infect"},{"issue":"12","key":"5906_CR19","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.ejso.2018.09.016","volume":"44","author":"CEL Klaver","year":"2018","unstructured":"Klaver CEL, Wasmann KATGM, Verstegen M, van der Bilt JDW, Nagtegaal ID, van Ramshorst B, Tanis PJ, Wolthuis AM, van Santvoort HC, de Wilt JHW, D\u2019Hoore A (2018) Postoperative abdominal infections after resection of T4 colon cancer increase the risk of intra-abdominal recurrence. Eur J Surg Oncol 44(12):1880\u20131888. https:\/\/doi.org\/10.1016\/j.ejso.2018.09.016","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"5906_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.4103\/0973-1482.147735","volume":"11","author":"M Cilekar","year":"2015","unstructured":"Cilekar M, Erkasap S, Oner U, Akici M, Ciftci E, Dizen H, Turel S, Kavak OI, Yilmaz S (2015) An atypical cause of rapidly progressing breast lump with abscess formation: pure squamous cell carcinoma of the breast. J Cancer Res Ther 11(4):1023. https:\/\/doi.org\/10.4103\/0973-1482.147735","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"5906_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/17474086.2018.1407645","volume":"11","author":"T Tadmor","year":"2018","unstructured":"Tadmor T, Welslau M, Hus I (2018) A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol 11(1):57\u201370. https:\/\/doi.org\/10.1080\/17474086.2018.1407645","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"5906_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","volume":"129","author":"MR Grever","year":"2017","unstructured":"Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129(5):553\u2013560. https:\/\/doi.org\/10.1182\/blood-2016-01-689422","journal-title":"Blood"},{"key":"5906_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-3-319-04220-6_11","volume":"161","author":"VA Morrison","year":"2014","unstructured":"Morrison VA (2014) Infections in patients with leukemia and lymphoma. Cancer Treat Res 161:319\u2013349. https:\/\/doi.org\/10.1007\/978-3-319-04220-6_11","journal-title":"Cancer Treat Res"},{"key":"5906_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1182\/asheducation-2013.1.423","volume":"2013","author":"TJ Walsh","year":"2013","unstructured":"Walsh TJ, Gamaletsou MN (2013) Treatment of fungal disease in the setting of neutropenia. Hematol Am Soc Hematol Educ Program 2013:423\u2013427. https:\/\/doi.org\/10.1182\/asheducation-2013.1.423","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"suppl 5","key":"5906_CR25","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111\u2013v118","journal-title":"Ann Oncol"},{"key":"5906_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2017.09.025","volume":"45","author":"T Knight","year":"2017","unstructured":"Knight T, Ahn S, Rice TW, Cooksley T (2017) Acute oncology care: a narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. Eur J Intern Med 45:59\u201365","journal-title":"Eur J Intern Med"},{"issue":"10","key":"5906_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cmi.2017.03.024","volume":"23","author":"N Horita","year":"2017","unstructured":"Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T (2017) Comparison of antipseudomonal \u03b2-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect 23(10):723\u2013729. https:\/\/doi.org\/10.1016\/j.cmi.2017.03.024","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"5906_CR28","doi-asserted-by":"publisher","first-page":"CD003038","DOI":"10.1002\/14651858","volume":"2013","author":"M Paul","year":"2013","unstructured":"Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L (2013) Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013(6):CD003038. https:\/\/doi.org\/10.1002\/14651858","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"5906_CR29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4065\/80.9.1146","volume":"80","author":"IA Bliziotis","year":"2005","unstructured":"Bliziotis IA, Michalopoulos A, Kasiakou SK, Samonis G, Christodoulou C, Chrysanthopoulou S, Falagas ME (2005) Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 80(9):1146\u20131156. https:\/\/doi.org\/10.4065\/80.9.1146","journal-title":"Mayo Clin Proc"},{"key":"5906_CR30","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00520-013-1758-y","volume":"21","author":"J Klastersky","year":"2013","unstructured":"Klastersky J, Paesmans M (2013) The Multinational Association for Supportive Care in Cancer (MASCC) risk score: 10 years of use for identifying low risk neutropenic cancer patients. Support Care Cancer 21:1487\u20131495","journal-title":"Support Care Cancer"},{"key":"5906_CR31","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1093\/annonc\/mdq745","volume":"22","author":"O Teuffel","year":"2011","unstructured":"Teuffel O, Ethier M, Alibhal S et al (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22:2358\u20132365","journal-title":"Ann Oncol"},{"issue":"4","key":"5906_CR32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.52964\/AMJA.0529","volume":"14","author":"T Cooksley","year":"2015","unstructured":"Cooksley T, Holland M, Klastersky J (2015) Ambulatory outpatient management of patients with low risk febrile neutropaenia. Acute Med 14(4):178\u2013181","journal-title":"Acute Med"},{"issue":"16","key":"5906_CR33","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038\u20133051. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.3038","journal-title":"J Clin Oncol"},{"issue":"14","key":"5906_CR34","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR (2018) Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 36(14):1443\u20131453. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211","journal-title":"J Clin Oncol"},{"issue":"5","key":"5906_CR35","first-page":"1465","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Rice TW, Yeung SJ, Cooksley T (2018) Comparison of the MASCC and CISNE scores for identifying low risk neutropenic fever patients: analysis of data from three emergency departments in cancer centers in three continents. Support Care Cancer 26(5):1465\u20131470","journal-title":"Support Care Cancer"},{"issue":"3","key":"5906_CR36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.52964\/AMJA.0720","volume":"17","author":"DS Lasserson","year":"2018","unstructured":"Lasserson DS, Harris C, Elias T, Bowen J, Clare S (2018) What is the evidence base for ambulatory care for acute medical illness? Acute Med 17(3):148\u2013153","journal-title":"Acute Med"},{"issue":"1","key":"5906_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.7861\/clinmedicine.18-1-69","volume":"18","author":"M Hamad","year":"2018","unstructured":"Hamad M, Connolly V (2018) Ambulatory emergency care \u2013 improvement by design. Clin Med 18(1):69\u201374","journal-title":"Clin Med"},{"issue":"9","key":"5906_CR38","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1007\/s00520-018-4194-1","volume":"26","author":"T Cooksley","year":"2018","unstructured":"Cooksley T, Campbell G, Al-Sayed T, Lamola L, Berman R (2018) A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) Clinic. Support Care Cancer 26(9):2937\u20132940","journal-title":"Support Care Cancer"},{"issue":"3","key":"5906_CR39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jemermed.2019.09.032","volume":"58","author":"W Marshall","year":"2020","unstructured":"Marshall W, Campbell G, Knight T, Al-Sayed T, Cooksley T (2020) Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits-real-world experience from a UK cancer center. J Emerg Med 58(3):444\u2013448","journal-title":"J Emerg Med"},{"issue":"1","key":"5906_CR40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.52964\/AMJA.0740","volume":"18","author":"E Marshall","year":"2019","unstructured":"Marshall E (2019) Ambulatory management in low risk neutropenic sepsis \u2013 a plea for integrated acute cancer care. Acute Med 18(1):5\u20136","journal-title":"Acute Med"},{"issue":"11","key":"5906_CR41","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 23(11):3131\u20133140. https:\/\/doi.org\/10.1007\/s00520-015-2686-9","journal-title":"Support Care Cancer"},{"issue":"28","key":"5906_CR42","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"14 Suppl 9","key":"5906_CR43","first-page":"16","volume":"20","author":"GH Lyman","year":"2006","unstructured":"Lyman GH (2006) Chemotherapy dose intensity and quality cancer care. Oncology (Williston Park) 20(14 Suppl 9):16\u201325","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"5906_CR44","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2217\/14796694.2.6.667","volume":"2","author":"R Ricotta","year":"2006","unstructured":"Ricotta R, Cerea G, Schiavetto I, Maugeri MR, Pedrazzoli P, Siena S (2006) Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia. Future Oncol 2(6):667\u2013676. https:\/\/doi.org\/10.2217\/14796694.2.6.667","journal-title":"Future Oncol"},{"issue":"10","key":"5906_CR45","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1002\/cam4.2395","volume":"8","author":"G Egan","year":"2019","unstructured":"Egan G, Robinson PD, Martinez JPD, Alexander S, Ammann RA, Dupuis LL, Fisher BT, Lehrnbecher T, Phillips B, Cabral S, Tomlinson G, Sung L (2019) Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials. Cancer Med 8(10):4536\u20134546. https:\/\/doi.org\/10.1002\/cam4.2395","journal-title":"Cancer Med"},{"issue":"7","key":"5906_CR46","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s00520-016-3183-5","volume":"24","author":"B Rapoport","year":"2016","unstructured":"Rapoport B, Klastersky J, Raftopoulos H, Freifeld A, Aoun M, Zinner SH, Rolston KV (2016) The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC \u201cNeutropenia, Infection and Myelosuppression\u201d Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013. Support Care Cancer 24(7):2819\u20132826. https:\/\/doi.org\/10.1007\/s00520-016-3183-5","journal-title":"Support Care Cancer"},{"key":"5906_CR47","unstructured":"Supportive care strategies during the COVID-19 pandemic. https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/supportive-care-in-the-covid-19-era (Accessed 21-July-2020)"},{"key":"5906_CR48","unstructured":"COVID-19 patient care information. Available at: https:\/\/www.asco.org\/asco-coronavirus-information\/care-individuals-cancer-during-covid-19 (Accessed 21-July-2020)"},{"key":"5906_CR49","unstructured":"ASCO Special report: a guide to cancer care delivery during the COVID-19 pandemic. May 19, 2020. Available from: https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/2020-ASCO-Guide-Cancer-COVID19.pdf (Accessed 21-July-2020)"},{"key":"5906_CR50","unstructured":"Hematopoietic growth factors short-term recommendations specific to issues with COVID-19 (SARS-CoV-2) https:\/\/www.nccn.org\/covid-19\/pdf\/HGF_COVID-19.pdf (Accessed 21-July-2020)"},{"key":"5906_CR51","unstructured":"Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. Evidence review, search strategies, health economics evidence review and health economics plan: developed for NICE by the National Collaborating Centre for Cancer 2012. UK - NICE. Available from: www.nice.org.uk \u203a evidence-review-188303582 (Accessed 21-July-2020)"},{"issue":"6","key":"5906_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565","journal-title":"J Clin Oncol"},{"issue":"2","key":"5906_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197\u2013198","journal-title":"JAMA"},{"key":"5906_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ejca.2012.08.025","volume":"49","author":"F Scott\u00e9","year":"2013","unstructured":"Scott\u00e9 F, Oudard S, Aboudagga H, Elaidi R, Bonan B (2013) A practical approach to improve safety and management in chemotherapy units based on the PROCHE - Programme for optimisation of the chemotherapy network monitoring program. Eur J Cancer 49:541\u2013544","journal-title":"Eur J Cancer"},{"key":"5906_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.03.020","volume":"132","author":"F Scott\u00e9","year":"2020","unstructured":"Scott\u00e9 F, Minvielle E, Mir O, Andr\u00e9 F, Barlesi F, Soria JC (2020) A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19-positive patients with cancer. Eur J Cancer 132:1\u20134. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.020","journal-title":"Eur J Cancer"},{"key":"5906_CR56","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1056\/NEJMp2003539","volume":"382","author":"JE Hollander","year":"2020","unstructured":"Hollander JE, Carr BG (2020) Virtually perfect? Telemedicine for COVID-19. N Engl J Med 382:1679\u20131681","journal-title":"N Engl J Med"},{"issue":"1","key":"5906_CR57","doi-asserted-by":"publisher","first-page":"e13436","DOI":"10.1111\/ijcp.13436","volume":"74","author":"T Cooksley","year":"2020","unstructured":"Cooksley T, Marshall W, Ahn S, Lasserson DS, Marshall E, Rice TW, Klotz A (2020) Ambulatory emergency oncology: a key tenet for future emergency oncology care. Int J Clin Pract 74(1):e13436","journal-title":"Int J Clin Pract"},{"issue":"10","key":"5906_CR58","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1007\/s00520-018-4235-9","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Cooksley T, Banala S, Buffardi L, Rice TW (2018) Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism. Support Care Cancer 26(10):3601\u20133607","journal-title":"Support Care Cancer"},{"issue":"5","key":"5906_CR59","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00520-015-3006-0","volume":"24","author":"C Font","year":"2016","unstructured":"Font C, Fernandez-Avil\u00e9s F, Calderon C et al (2016) Home management of acute medical complications in cancer patients. Support Care Cancer 24(5):2129\u20132137","journal-title":"Support Care Cancer"},{"key":"5906_CR60","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.18.01167","volume":"37","author":"NR Handley","year":"2019","unstructured":"Handley NR, Bekelman JE (2019) The oncology hospital at home. J Clin Oncol 37:448\u2013452","journal-title":"J Clin Oncol"},{"issue":"19","key":"5906_CR61","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.20.00960","volume":"38","author":"JM Marron","year":"2020","unstructured":"Marron JM, Joffe S, Jagsi R, Spence RA, Hlubocky FJ (2020) Ethics and resource scarcity: ASCO recommendations for the oncology community during the COVID-19 pandemic. J Clin Oncol 38(19):2201\u20132205. https:\/\/doi.org\/10.1200\/JCO.20.00960","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05906-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-020-05906-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05906-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T11:30:28Z","timestamp":1669721428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-020-05906-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5906"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05906-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"3 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Rapoport reports grants, personal fees, non-financial support, and advisory boards and is a speaker engagement from Sandoz and speaker engagement from Amgen South Africa, during the conduct of the study. Dr. Scotte reports grants, personal fees, and other from AMGEN; personal fees and other from Mylan; grants, personal fees, and other from Roche; personal fees and other from Mundipharma; personal fees and other from Leo Pharma; personal fees and other from Tesaro; personal fees and other from Helsinn; personal fees and other from Tilray; personal fees and other from Vifor Pharma; personal fees and other from Pfizer; personal fees and other from BMS; and personal fees and other from Pierre Fabre Oncology, outside the submitted work. The other authors declare no conflicts of interest.No ethics approval is required for this position paper.There is no patient consent for participation or publication relevant to this position paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}